Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 6/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14998240 | 1.00 | KCNH2 (0.46) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2564200 | 0.94 | KCNH2 (0.51) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12289871 | 0.94 | KCNH2 (0.51) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL17249662 | 0.94 | KCNH2 (0.51) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12289866 | 0.94 | KCNH2 (0.51) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL16524262 | 0.91 | KCNH2 (0.43) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2574727 | 0.91 | KCNH2 (0.43) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL14998251 | 0.91 | KCNH2 (0.43) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12286714 | 0.91 | KCNH2 (0.43) | KCNH2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL14998353 | 0.91 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | KCNH2 441/4885NPC1 3233/4885ALDH1A1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.